Patent: 8,247,536

Summary for Patent: 8,247,536

Title:	Factor VIII compositions
Abstract:	Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.
Inventor(s):	Bossard Mary J., Bentley Michael D., Zhang Ping
Assignee:	Nektar Therapeutics
Application Number:	US12636594
Patent Claims:	see list of patent claims

Details for Patent 8,247,536

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc	REFACTO	antihemophilic factor (recombinant)	For Injection	103779	June 27, 2001	8,247,536	2029-12-11
Wyeth Pharmaceuticals Llc	REFACTO	antihemophilic factor (recombinant)	For Injection	103779	July 06, 2001	8,247,536	2029-12-11
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	November 13, 2015	8,247,536	2029-12-11
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	October 25, 2016	8,247,536	2029-12-11
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	March 13, 2017	8,247,536	2029-12-11
Novo Nordisk Inc.	ESPEROCT	antihemophilic factor (recombinant), glycopegylated-exei	For Injection	125671	February 19, 2019	8,247,536	2029-12-11

International Patent Family for US Patent 8,247,536

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004075923
United States of America	9999657
United States of America	8889831
United States of America	8618259
United States of America	8519102
United States of America	8143378